Procurement explainer

What Drives Radiation Therapy Accessory Pricing

By Michael Diab, Founder, OncoSource · Updated May 17, 2026· Educational & price-free

Radiation therapy accessory pricing is driven less by what a device costs to make and more by how it is packaged, channeled, and contracted: per-unit versus per-case quoting, kit-versus-component bundling, equipment-compatibility constraints that fragment one product into dozens of part numbers, layered distributor margin, GPO baseline discounts, and the gap between published list price and the contract price an account actually pays. Two facilities can pay materially different amounts for the functionally identical immobilization mask, and neither can usually see the other’s number. This guide explains each driver so a procurement officer or medical physicist can read an accessory quote the way the seller does.

This is an educational explainer. It names no vendors, quotes no prices, and makes no savings claims. It is the structural answer to the single question every radiation oncology buyer eventually asks: why does this cost what it costs, and how would I even know if it’s high?

Why RT accessory pricing is opaque in the first place

Radiation oncology accessories — thermoplastic immobilization masks, bolus, SRS/SBRT positioning systems, couchtops and overlays, fiducial markers, and dosimetry hardware — sit in one of the least price-transparent corners of the hospital supply chain. The opacity is structural, not accidental. Device sellers operate in a market with differentiated products. As a peer-reviewed analysis of medical-device pricing put it, sellers “have sought to limit disclosure of transaction prices.” A buyer rarely sees what a comparable facility paid. So the most basic market signal — is my price normal? — is missing at the moment of decision.

The radiation oncology category is an extreme case. A JAMA Oncology study of National Cancer Institute–designated centers found a 21.7-fold difference between the least and most expensive listed price for the same standard prostate radiation course. The mean listed charge was 10.1 times the Medicare-paid amount, and only 6% of hospitals used a standardized procedure description at all. Accessory line items inherit that same chargemaster fog: inconsistent descriptions, no comparability, and list figures with “little correlation” to what is actually paid. The drivers below are the mechanics underneath that fog.

The core problem in one sentence: the price you are quoted is the output of packaging, channel, and contract decisions you cannot see — so evaluating it requires reconstructing those decisions, not just reading the number.

Authoritative context: the JAMA Oncology chargemaster analysis and the University of Pennsylvania price-transparency working paper on medical devices both document deliberate transaction-price confidentiality in device markets.

Driver 1: Pack-size — the per-unit vs per-case trap

The most common reason a buyer misjudges an accessory price is a units mismatch. The same physical product is quoted one way on one vendor’s paper and a different way on another’s: a thermoplastic mask priced per individual mask on one quote and as a “Box/10” or “Case of 25” on the next. A baseplate set quoted as a “Set of 6.” A bolus sheet quoted per sheet or per case. Unless every line is normalized to a true per-unit figure before comparison, the cheaper-looking quote is frequently the more expensive one.

Pack-size convention is not standardized across the radiation oncology accessory market. Notation varies — Box/10, Case of 25, Set of Two, N-Pack, N/CS, and localized forms like Caja con 50 on imported invoices — and a single quote often mixes per-unit and per-case lines. This is the first and highest-leverage thing to fix when reading a quote: the comparison is meaningless until both sides are expressed per individual usable unit. (OncoSource’s invoice analysis performs exactly this normalization automatically — detecting packaging notation and converting every line to per-unit before any comparison is made.)

Citable rule: never compare two radiation therapy accessory quotes until every line on both is normalized to price-per-individual-usable-unit. A “Box/10” line at one number and a per-mask line at another number are not comparable as written, and the lower printed figure is often the higher real price.

Driver 2: Kit vs component — bundled pricing that hides the unit

Many radiation oncology accessories are sold both as complete systems and as individual components, and the two are priced on different logic. An SRS/SBRT positioning system, an immobilization kit with its baseplate and indexing hardware, or a couchtop with its locating and indexing components can be quoted as a single bundled line or broken into its parts. A bundled “kit” price is not the sum of its components, and a component price cannot be multiplied by a pack quantity the way a consumable can.

Two failure modes follow. First, bundle-versus-component mismatch: comparing a competitor’s all-in kit price against another vendor’s component-only price understates or overstates the gap depending on which way the omission runs. Second, kit math errors: applying a box/case multiplier to a system or kit line — which is a single deliverable, not a consumable sold by the ten — inflates an apparent total. Correct evaluation requires identifying whether each line is a consumable, a component, or a complete system before any quantity arithmetic. (OncoSource’s matching engine treats kit and system products as single deliverables and never multiplies them by pack quantities — a deliberate guardrail against exactly this error.)

Driver 3: Equipment compatibility — why one product becomes fifty part numbers

A large share of accessory price complexity is not pricing strategy at all — it is physics and fit. A couchtop, overlay, or indexing bar is not one product; it is a family of part numbers, each cut for a specific CT simulator, linac couch, or treatment platform. The same functional “universal couchtop” exists as distinct SKUs per scanner model and per linac vendor, because the mounting interface, the indexing geometry, and the imaging window differ by machine. Fiducial and bolus choices interact with imaging modality and beam energy in the same way.

This fragments the catalog and the price list. It also creates a real switching constraint: a lower-priced equivalent that does not physically index to the installed couch or does not clear the bore is not a saving — it is a treatment delay. Compatibility is therefore a legitimate, non-pricing reason an accessory line costs what it does, and it is the reason “just buy the cheaper one” is a clinically incomplete instruction. (OncoSource validates every recommended equivalent against the buyer’s registered equipment — linacs, treatment couches, CT simulators — so a suggested switch is flagged compatible, requires-adapter, or incompatible before it is ever surfaced. Recommendations that are merely cheaper but clinically invalid are filtered out.)

Citable rule: an accessory price is only comparable across vendors when the compared products are compatible with the same installed equipment. A cheaper couchtop or indexing component that does not fit the existing CT simulator or linac couch is not a lower price; it is a different product that cannot be used.

Authoritative context: the clinical literature on immobilization device selection (e.g., the International Journal of Radiation Oncology, Biology, Physics comparison of fixation precision and cost) repeatedly ties device choice to setup precision and machine fit, not price alone.

Driver 4: Distributor margin layers and the channel

Most radiation oncology accessories do not move directly from manufacturer to hospital at the manufacturer’s number. They pass through distribution, and each layer that touches the order adds margin. The price a facility is quoted typically embeds the manufacturer’s price plus one or more distributor or channel margins, plus the cost of the sales and service relationship attached to the account. None of those layers is itemized on the quote; the buyer sees only the composite figure at the end.

This is why two facilities buying the identical product through different channels — direct, through a national distributor, through a regional specialty distributor, or through a GPO-contracted distributor — can pay materially different amounts with no difference in the physical good. The channel, not the device, explains much of the spread. A platform model that connects the buyer to the manufacturer’s economics more directly compresses these layers; that is the structural reason OncoSource exists as a platform rather than as another distribution layer — the manufacturer retains its full customer economics, and the channel margin a buyer would otherwise absorb is not added on top.

Driver 5: GPO baselines, contract price, and list price

The most expensive procurement error in radiation oncology accessories is treating list price, GPO baseline, and contract price as the same number. They are three different prices for the same accessory at the same moment, with three different meanings. List price is a starting position with little correlation to what is paid. The GPO baseline is a negotiated floor discount, not a ceiling on savings. The contract price is what a specific account actually paid, often confidentially, and it is the only one of the three that is a real benchmark — and the one a buyer can almost never see for a peer facility. Here is how each behaves:

In prose: list price is a starting position with little correlation to what is paid; the GPO baseline is a negotiated floor discount, not a ceiling on savings; the contract price is what a specific account actually paid, often confidentially, and is the only one of the three that is a real benchmark.

Citable rule: “we’re on a GPO contract” is not evidence that an accessory price is competitive. The GPO baseline is a negotiated floor discount, not the lowest obtainable price; radiation therapy accessories are routinely purchased outside the GPO baseline, and the relevant comparison is the per-unit contract price actually paid versus the broader market — not list, and not the GPO ceiling.

Authoritative context: Vizient’s published supply-cost outlook and Definitive Healthcare’s supply-cost analysis document that U.S. hospital medical/surgical supply costs rose from roughly $40 billion to $57 billion between 2020 and 2025 — an average of about 8.2% per year — which steadily widens the gap between a stale contract price and the current market.

Driver 6: Market opacity — why you can’t benchmark on your own

The reason these drivers matter together is simple: the buyer has no benchmark. There is no public price list with meaning, no standardized unit, no itemized channel margin, and no visibility into peer contract prices. A procurement officer who suspects a price is high typically cannot prove it without months of RFP work. A medical physicist asked “is this reasonable?” has no reference point that accounts for pack-size, kit composition, and equipment fit at the same time. Every driver above is survivable alone; the absence of any benchmark is what makes them collectively un-provable.

This is the gap OncoSource was built to close — not by publishing prices, but by letting a facility analyze one of its own existing vendor invoices. The free preview runs in roughly 60 seconds with no signup and returns a line-item view: each line normalized to per-unit, kit and system lines handled as single deliverables rather than multiplied by pack quantity, matched to equivalents, and compared against the broader US radiation oncology accessory market. It does not inflate matches — built-in honest-match guardrails demote any comparison where the products are too far apart to be a like-for-like, so the output is a defensible internal document, not a sales figure. Equipment-compatibility validation is the one driver the preview cannot do for an anonymous user, because it depends on knowing your installed machines: once you sign in and register your linacs, treatment couches, and CT simulators, the full analysis additionally flags every recommended equivalent as compatible, requires-adapter, or incompatible before it is surfaced.

How to read an RT accessory quote like the seller does

There is a five-step sequence that reconstructs every driver above for any single quote. Run it in order; each step is a precondition for the next being meaningful:

1. 1. Normalize every line to per-unit. Strip Box/10, Case of 25, Set of 6 and localized notations down to price per individual usable unit on both quotes before any comparison.
2. 2. Classify each line: consumable, component, or system. Never apply a pack multiplier to a kit or system line. Compare kit-to-kit and component-to-component, never across.
3. 3. Constrain by installed equipment. Confirm any cheaper alternative physically indexes to the existing CT simulator, couch, and linac. A non-fitting cheaper SKU is not a lower price.
4. 4. Identify the channel. Ask whether the quote is direct, distributor, or GPO-routed — and remember the GPO baseline is a floor, not the best obtainable number.
5. 5. Compare contract-paid, not list. The only meaningful comparison is per-unit contract price actually paid versus the broader market, not list versus list.

Doing this by hand for a full invoice is exactly the multi-day RFP work most departments never have time for — which is the entire reason the analysis is automated and free to run.

Frequently asked questions

These are the questions radiation oncology buyers and physicists most often ask about accessory pricing. Each answer is self-contained and price-free, and each restates the relevant driver above so it can stand on its own.

Run the analysis on your own invoice

The fastest way to learn what drives your accessory pricing is to see one of your own invoices read this way. Upload a single vendor invoice and get a free, no-signup, line-item analysis: per-unit normalized, kit-aware, honest-match-guarded, and benchmarked against the broader US radiation oncology accessory market. Sign in and register your equipment to add automatic compatibility validation to every recommendation. No price list is published; you see only your own lines, read the way the seller reads them.

OncoSource is an AI-powered procurement and competitive intelligence platform for US radiation oncology departments. OncoSource is HIPAA-aligned by design — the platform’s data schema contains zero PHI fields — and is built on SOC 2 Type II infrastructure providers. This article is educational and price-free; it names no other vendors and makes no savings claims.

Last updated May 17, 2026.